Ananda Lee

Benjamin Camavdic

Gesellschaftsrecht / M&A

IP / IT

Wettbewerb

Steuern

Arbeitsrecht und Vergütung für Führungskräfte

On January 4, 2021, CeramTec GmbH (CeramTec), a leading international manufacturer of technical ceramics, announced its acquisition of all shares in Dentalpoint AG, a Swiss specialist for ceramic dental implants.
Homburger advised CeramTec on the transaction. The Homburger team was led by senior partner Daniel Daeniker and included lead associate Carlo Sulser (both Corporate / M&amp;A), partners Andri Hess (IP / IT) and Richard Stäuber (Competition), associates Laetitia Fracheboud (Tax), Valentin Fluor, Philippe Baumann (both IP / IT), and Nicole Hilpert (Employment and Executive Compensation), and junior associates Vincent Croisier, Ananda Lee, and Benjamin Camavdic (all Corporate / M&amp;A).

Homburger advised CeramTec on the acquisition of Dentalpoint

Regulierung

Datenschutz

Finanzierungen und Anlageprodukte

Avaloq_bw

On December 22, 2020, Avaloq Group (Avaloq), a Swiss-based global leader in digital banking solutions, core banking software and wealth management technology, announced that Japan-based NEC Corporation (NEC, TSE:6701) had completed its acquisition of Avaloq. In the transaction, NEC acquired all outstanding shares from the existing shareholders, which includes the founders, current and former employees as well as private equity firm Warburg Pincus, at an enterprise value exceeding CHF 2 bn.
Homburger acted as global transaction counsel to Avaloq and the majority shareholders. The Homburger team was led by partner Heinz Schärer and included partner David Oser, associates Philippe Baumann and Angela Oppliger and junior associate Cédric Berger (all Corporate / M&amp;A), partner Marcel Dietrich and associates Allegra Arnold and David Waldmeier (all Competition, Regulatory), partners Georg Rauber and Luca Dal Molin and associates Valentin Fluor and Kirsten Wesiak-Schmidt (all IP / IT and Data Protection), partner Jürg Frick and associate Pierina Janett-Seiler (both Financing and Investment Products), as well as associate Marc Vogelsang (Tax).

Homburger advised Avaloq Group and majority shareholders in the completion of NEC Corporation's acquisition of Avaloq Group

Vifor

On November 9, 2020, Vifor Pharma and Angion Biomedica Corp. announced the signing of a licensing agreement for the commercialization of Angion’s ANG-3777 molecule developed for treatment of delayed graft function (DGF) and cardiac surgery-associated acute kidney injury (CSA-AKI). Under the terms of the agreement, Vifor Pharma has been granted an exclusive license for commercializing ANG-3777 nephrology indications worldwide except Greater China. Further, Vifor Pharma has, apart from upfront, clinical and commercial milestone payments as well as royalty payments, agreed to a considerable equity investment in Angion.
Homburger AG acted as legal counsel to Vifor in connection with the legal due diligence review of Angion’s development activities and the drafting, negotiation and final documentation of the license agreement. The Homburger team was led by partner Georg Rauber (IP / IT) and included associates Carola Winzeler (IP / IT), Valentin Fluor (IP / IT; Corporate / M&amp;A) and junior associate Emily Zurfluh.

Valentin
Fluor

Homburger advised CeramTec on the acquisition of Dentalpoint

Homburger advised Avaloq Group and majority shareholders in the completion of NEC Corporation's acquisition of Avaloq Group

Homburger advised Vifor

Join the Team

Valentin Fluor

Karriere

Sprachen

Zulassung

Teams

ValentinFluor

Homburger advised CeramTec on the acquisition of Dentalpoint

Homburger advised Avaloq Group and majority shareholders in the completion of NEC Corporation's acquisition of Avaloq Group

Homburger advised Vifor

Join the Team

Valentin Fluor

Karriere

Sprachen

Zulassung

Teams

Valentin
Fluor